Top 5 Stories of 2018
The most-read stories on Psych Congress Network in 2018:
Smoking cannabis eases symptoms of depression, anxiety, and stress shortly after use, but depressive symptoms are likely to worsen over time, according to a study published online in the Journal of Affective Disorders.
In patients with treatment-refractory anxiety who responded to ketamine, weekly maintenance doses over 3 months were well tolerated and significantly improved social and work functioning, according to a small study published online in the Journal of Psychopharmacology.
Cariprazine, lurasidone, olanzapine, combination olanzapine-fluoxetine, and quetiapine are significantly more effective than placebo in easing symptoms of acute bipolar depression, according to a meta-analysis.
A novel drug being developed for the treatment of major depressive disorder (MDD) has been awarded Breakthrough Therapy designation from the US Food and Drug Administration (FDA), following positive results in a Phase 2 trial.
The US Food & Drug Administration (FDA) has approved a new indication for Abilify Maintena (aripiprazole), making it the first once-monthly, long-acting injectable approved for maintenance monotherapy treatment of bipolar I disorder in adults.